TY - CHAP M1 - Book, Section TI - Adduct-Forming Agents: Alkylating Agents and Platinum Analogs A1 - Chabner, Bruce A. A2 - Chabner, Bruce A. A2 - Longo, Dan L. Y1 - 2016 N1 - T2 - Harrison's Manual of Oncology, 2e AB - Since the first clinical experiments with nitrogen mustard at Yale in the early 1940s, alkylating agents have played a primary role in cancer treatment (1). The early mustards have gradually been replaced by platinum-based compounds in most regimens for treating epithelial cancers, but remain primary components in the treatment of childhood solid tumors, lymphomas, and adult sarcomas, and in high-dose chemotherapy. As a class, they have the features of the prototypical cytotoxic drugs, with broad antitumor activity, but they adversely affect many normal tissues as well. They share common characteristics of a significant increase in response as doses are escalated: acute toxic effects on bone marrow, epithelium of the gastrointestinal tract, and hair follicles; significant toxicity to lung, heart, and central nervous systems at bone marrow ablative doses; and late induction of myelodysplasia and acute leukemia. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/11/05 UR - hemonc.mhmedical.com/content.aspx?aid=1127646482 ER -